Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children

AIDS

Volumn 12, Issue 5, 1998, Pages 489-494

  Horneff, Gerd ^a   Adams, Ortwin ^a   Wahn, Volker ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

AIDS; Children; Combination therapy; HIV; Lamivudine; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GRANULOCYTE ANTIBODY; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; CHILD; CLINICAL ARTICLE; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; NEUTROPENIA; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT; LAMIVUDINE; MALE; PILOT PROJECTS; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 0032568239     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199805000-00010     Document Type: Article

References (26)

1. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
2. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
3. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
4. Saravolatz LD, Winslow DL, Collins G, et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1099-1106.
5. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. JAMA 1996, 276:46-54.
6. Mueller BU, Pizzo PA, Farley M, et al.: Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr 1994, 125:142-146.
7. Husson RN, Mueller BU, Farley M, et al.: Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection. Pediatrics 1994, 93:316-322.
8. Kline MW, Fletcher CV, Federici ME, et al.: Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 1996, 97:889-890.
9. Sölder B, Wintergerst U, Notheis G, et al.: Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus. J Pediatr 1997, 130:293-299.
10. Englund JA, Baker CJ, Raskino C, et al.: Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med 1997, 336:1704-1712.
11. Luzuriaga, K, Bryson, Y, Krogstad P, et al.: Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997, 336:1343-1349.
12. Centers for Disease Control and Prevention: 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994, 43:1-10.
13. Centers for Disease Control and Prevention: 1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia in children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995, 44:1-11.
14. Wahn V, Yokota S, Meyer KL, et al.: Expansion of a maternally derived monoclonal T cell population with CD3+/CD8+/TCR-gamma/delta+ phenotype in a child with severe combined immunodeficiency. J Immunol 1991, 147:2934-2941.
15. McKinney RE, Maha MA, Connor EM, et al.: A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 1991, 324:1018-1025.
16. Brady MT, McGrath N, Brouwers P, et al.: Randomized study of tolerance and efficacy of high-versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). J Infect Dis 1996, 173:1097-1106.
17. Pizzo PA, Eddy J, Falloon J, et al.: Effect of continuous intravenous infusion of zidovudine (ZDV) in children with symptomatic HIV infection. N Engl J Med 1988, 319:889-896.
18. Ünal A, Lorenzo E, Brown M, et al.: Reverse transcriptase mutations in HIV-1-infected children treated with zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:140-145.
19. Ogino MT, Dankner WM, Spector SA: Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. J Pediatr 1993, 123:1-8.
20. Lewis LL, Venzon D, Church J, et al.: Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1996, 174:16-25.
21. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
22. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
23. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. JAMA 1996, 276:118-125.
24. Staszewski S, Loveday C, Picazo JJ, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA 1996, 276:111-117.
25. Bartlett JA, Benoit SL, Johnson VA, et al.: Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 125:161-172.
26. Staszewski S, Hill AM, Bartlett J, et al.: Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997, 11:477-483.